INTRODUCTION
The participation of Hageman factor in the kininforming, intrinsic clotting, and fibrinolytic systems has been clearly established (1) (2) (3) (4) (5) (6) (7) (8) (9) . Two mechanisms of activation of the Hageman factor molecule in vitro have been described (10) : solid-phase activation involving contact with a negatively charged surface, and fluid-phase activation in which proteolytic enzymes such as kallikrein, plasmin, or trypsin activate the Hageman factor. The transformation of Hageman factor on a negatively charged surface to a biologically active form does not appear to involve any cleavage of the molecule (10) . By contrast, activation of Hageman factor by the action of proteolytic enzymes is accompanied by cleavage of the native molecule although the actual sites have not been defined nor all the resulting fragments identified. This is publication no. 778 from the Scripps Clinic and Research Foundation.
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In the present study we 
METHODS
In all stages of purification, storage, assay, and experimentation, contact of Hageman factor with glass was avoided. Where plastic pipettes or containers could not be used, glassware was coated with a 1% silicone solution (Siliclad, Clay-Adams, Inc., Parsippany, N. J.). Column eluates were monitored by measuring their resistances which were then, for simplicity, converted to ionic strengths based on NaCl standards. Plasmin. Plasmin was obtained from purified human plasminogen (kindly supplied by Doctors J. A. Brockman, E. C. DeRenzo, and P. H. Bell of Lederle Laboratories, Pearl River, N. Y.) by incubation with 180 U streptokinase (Lederle Laboratories)/40 ug plasminogen for 10 min at 370 C. This material had a specific activity of 34 CTA2 U/mg using the casein assay described by Johnson, Kline, and Alkjaersig (14) . Before activation the plasminogen gave a single band on SDS-polyacrylamine gel.
Assay of the ability of Hageman factor to activate prekallikrein. The ability of Hageman factor or its fragments to activate prekallikrein was tested as follows: samples not exceeding 0.2 ml were brought to neutral pH with 0.1 M Tris buffer pH 7.6 in plastic tubes before the addition of 0.1 ml containing 1.25 Atg rabbit prekallikrein (3.1 ,ug when minimal activity was expected). After incubation at 370C for 20 min, 3 ml of 1 mM BAEe in 0.01 MI Tris buffer pH 7.6 containing 0.15 'M NaCl was added to each assay tube. At 20 min and again at later times if necessary, absorbance of the solutions was measured at 253 nm which is specific for the benzoyl arginine cleaved from BAEe by kallikrein, thus giving a qualitative measurement of the amount of active Hageman factor in the assay tube. If unactivated Hageman factor were to be assayed, it was first converted to an active form. Generally this was accomplished by adding 0.2 ,ug trypsin (2 X crystallized, Worthington Biochemical Corp., Freehold, N. J.) to the sample (pH 7-8), incubating 20 min at 370C, and blocking the trypsin with at least 10 ugg ovomucoid trypsin inhibitor (OMTI, Worthington Biochemical Corp.), before the addition of prekallikrein. Alternatively, the molecule could be converted to a form also capable of cleaving prekallikrein by absorption onto 500 ,g kaolin for 15 min at 220C, removal of the supernate after a brief centrifugation, followed by addition of prekallikrein to the kaolin precipitate. (It must be noted that the ratio of kaolin to Hageman factor is critical and often a dose-response curve must be made if optimal activation is desired [10] (Fig. 1) . Although the molecule appeared to be a single polypeptide chain, it was possible that cysteines involved in interchain disulfide bonds might be positioned within the three-dimensional structure in such a way that they might have resisted reduction under the conditions used. A stronger denaturant, 6 M guanidine, was employed, and reduction of labeled HHF was performed with mercaptoethanol followed by alkylation with bromoacetate (see Methods). A Drop Number 5% FIGURE 6 Sucrose density ultracentrifugation of HHF treated with kallikrein (same material as in Fig. 5 ). Sedimentation was for 17 h at 45,000 rpm. Assays as in Fig. 2 the sucrose gradient shows a biphasic profile with peaks at 4.5S and approximately 3.0S. Cleavage and activation under these conditions were not complete; that is, material remained which was 80,000 in mol wt and sedimented at 4.5S. Although this uncleaved portion of the sample had little prekallikrein-activating ability, such activity could be generated by treating the 4.5S region with trypsin as noted in Fig. 6 . The material which did contain the biologic activity sedimented at approximately 2.6-3.0S but whether this represented the 30,000, 40,000, or 52,000 mol wt fragment observed on SDS gels could not be determined from these experiments.
Treatment with plasmin. 80 cg plasmin (0.2 ml) was incubated with 0.2 ml Hageman factor containing trace quantities of [1"I]HHF for 30 min at 370C. A small aliquot was removed, treated with dithiothreitol in the presence of 12 M urea, alkylated with iodoacetamide, and subjected to electrophoresis in SDS acrylamide gels. The result is shown in Fig. 7 . Peaks are observed at 80,000, 52,000, 40,000, 30,000, and < 18,000. The remainder of the plasmin-treated sample was sedimented at 45,000 rpm for 17 h in a 5-20% sucrose gradient. As shown in Fig. 8 Identification of the Hageman factor fragment containing prekallikrein-activating capacity after enzymatic degradation
To determine whether the active site for prekallikrein activation resided in the 52,000, 40,000, or 28,000 mol wt peak obtained with enzymatic treatment, it was necessary to separate these fragments without destroying the activity of the molecule (gel filtration and sucrose gradient ultracentrifugation proved unsuccessful in this regard). Electrophoresis in 7% polyacrylamide gels yielded a multipeak pattern of ['«I]HHF treated with trypsin for 10 min (Fig. 9, bottom panel) . The presence of the three fragments as well as a small amount of uncleaved 80,000 mol wt material was confirmed by SDS-acrylamide electrophoresis before the sample was applied to the polyacrylamide gels not containing SDS. Elution of the polyacrylamide gel slices with 0.2 ml Tris-buffered saline into BSA-coated siliconized tubes enabled us to perform assays to determine Polyacrylamide Gel Section Number I+) FIGURE 10 Analysis by SDS acrylamide gels of the molecular weights of radiolabeled protein fragments present in four slices from a polyacrylamide gel of trypsin-treated Hageman factor (similar sample as in Fig. 9 ). Each of the designated slices was placed on top of a regular SDS acrylamide gel, overlayed with SDS buffer, and subjected to electrophoresis as usual. The SDS gels were then sectioned and counted for radioactivity. The percent of the total counts occurring in the positions known to correspond with mol wt of 80,000, 52,000, 42,000, and 28,000 are indicated.
in which fragment the biologic activity resided. Ability to activate prekallikrein directly or after incubation with 0.1 Ag trypsin was tested using 50-Al aliquots of the gel eluates. Both assays showed a single sharp peak associated with the fragment migrating coincident with BSA ( Fig. 9, top panel) . The mol wt of the various peaks obtained on polyacrylamide electrophoresis were determined by placing individual gel slices directly on top of SDS acrylamide gels, overlaying with buffer, and conducting the electrophoresis in the usual manner. The percentage of total radioactiv ity in the mol wt regions of 80,000, 52,000, 40,000, and 28,000 were computed for each polyacrylamide slice tested. The results are shown in Fig. 10 . By comparing the radioactivity profile with that of Fig. 9 . it can be seen that the prekallikrein-activating potential lies in the 28,000 fragment.
DISCUSSION
The data show HHF to be a single polypeptide chain. A mol wt value of 80.000 was obtained by electrophoresis in acrylamide gels containing SDS under reducing conditions. Using this mol wt, a computation of the number of residues of each amino acid per Hageman factor molecule was made after an amino acid analysis of a purified preparation (Table II) The HHF molecule has been shown to be cteaved at two primary sites during activation by various enzymes: trypsin, plasmin, kallikrein (the possibility exists of potential conitamination of the kallikrein with plasminogen activator contributing to the results obtained with this enzyme). This is presented diagramatically in Fig. 11 . Knowledge of the patterns of cleavage of HHF by enzymes from the plasma will be of considerable help in defining the mechanisms of activation of the molecule in vivo. Activation in solid phase by negatively charged surfaces is not accompanied by cleavage of the molecule (10) , while enzymes from the plasma activate and cleave Hageman factor (8, 10, 11) . The importance of the cleavage in directing activity along a particular pathway, i.e. the kinin forming, intrinsic clotting, or fibrinolytic systems, has yet to be defined.
The active site on Hageman factor, as defined by the ability to activate prekallikrein to kallikrein, is clearly associated with the 28,000 mol wt fragment that results from enzymatic activation. Studies to show that this fragment. exclusively, also contained the region responsible for activation of clotting factor XI were not definitive. Clotting assays performed on the polyacrylamide gel eluates showed clot-promoting ability associated with the most cathodal peak as well as the anodal 28,000 mol wt peak. Since the cathodal peak contained both the uncleaved 80,000 mol wt molecule, which was known to have clotting potential, and the 52,000 mol wt fragment, the absence of a factor XI-activating site on the 52,000 mol wt fragment could not be confirmed. The association of some clotting activity with the 28,000 mol wt peak, however, supports earlier reports of a Hageman factor-derived molecule of this size possessing the capacity to induce clotting in Hageman trait plasma (7, 24) . The ability of the fragments to activate plasminogen proactivator was not tested in these experiments. However, Kaplan and Austen have reported such capacity associated with low mol wt fragments of Hageman factor (9) .
The two sites of trypsin cleavage appear to be equally sensitive to the enzyme. When the initial cleavage yields the 52,000 and 28,000 fragments, however, the 52,000 is rapidly cleaved at the 40,000 position. The remaining fragment of 12,000 daltons is usually not seen as a discrete peak implying either a further breakdown of the peptide or perhaps a deficiency in this region of tyrosine residues which would couple the iodine-125.
That the overall charges of the fragments produced by trypsin treatment of HHF are similar is suggested by the observance that they migrate in alkaline polyacrylamide gels in order of decreasing mol wt.
Hageman factor of rabbit origin differs structurally from that of the human molecule (25) . It has been found to he a molecule of approximately 90,000 mol wt composed of three polypeptide chains linked by disulfides near the ends of the chains. Upon either reduction or trypsin treatment, it yields fragments of 30,000 mol wt. Why the structure of these two functionally similar molecules should differ so greatly is of considerable interest. Several possible explanations present themselves: the rabbit Hageman factor may be initially synthesized as a single polypeptide chain but upon release from its RNA template or secretion from its cell of origin becomes cleaved between disulfide linkages. Such a situation exists with several other proteins, such as insulin (26) . Alternatively, the rabbit Hageman factor could undergo partial cleavage during purification at points between intrachain disulfide bonds; or, the molecules from the two species may indeed differ structurally in their native form.
